Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up - Wikidata - awgldk - TriplyDB

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

http://www.wikidata.org/entity/Q35572611

about

Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease Recent advances in the neuropsychopharmacology of serotonergic hallucinogens Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis Pimavanserin for the treatment of Parkinson's disease psychosis.Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Behavioral effects of levodopa.Lewy body dementias.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Pathophysiology and treatment of psychosis in Parkinson's disease: a review.Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.An update expert opinion on management and research strategies in Parkinson's disease psychosis Present and future drug treatment for Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Treatment of behavioural symptoms and dementia in Parkinson's disease.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs.Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies.The management of psychosis in movement disorder patients.Management of the behavioral aspects of Parkinson's disease.Advances in the treatment of visual hallucinations in neurodegenerative diseases.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia.Treatment of dementia with lewy bodies Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital.Nonmotor symptoms in Parkinson's disease.Atypical antipsychotic drugs in the treatment of Parkinson's disease.5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.The serotonergic system in motor and non-motor manifestations of Parkinson's disease.Treating psychosis in movement disorder patients: a review.Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders.Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.Therapy-resistant symptoms in Parkinson's disease.The psychosis spectrum in Parkinson disease.

P2860

Q24680260-0937489C-24E6-47B2-B321-C6597338150A Q26738456-36379FD6-7B88-4B55-9145-E2E2EA60E018 Q27027381-2CC461F3-0FC9-4E10-923C-9F1C2FA61291 Q28074468-49B6F68C-011D-48C6-BAB6-24AEDF6CD227 Q30249553-D3E21B3C-4CD1-4778-92FD-2C28811E5B94 Q30489967-9783F4E6-041B-4E5C-9B67-38D7C78379AB Q33607256-AE2A4E84-6053-450C-8E48-25F60870CB31 Q33957582-C944D404-2F13-49CC-A179-50F8E670AFF6 Q34369646-21545DDD-965E-4394-AAC8-FBCE417133DA Q34388686-A9F264AD-942F-4BCC-B9C5-C3001AB115AF Q34452922-EC088FA6-F09D-405E-9CFF-6ED89D71F232 Q34502646-DB37F944-9B8C-4417-ABDE-D1AA82A5A79F Q34610593-FB374B9E-7CC6-4D3E-9F29-4C4DB241BD3E Q34610608-FFD9D9CF-EE9B-433E-BBE9-383561152749 Q34758986-02876FF3-41E4-4365-9FE2-39E2C8B63B24 Q35124915-9EC93AE2-EC4D-417B-9EE1-249F4E75F582 Q35154278-8C0119EA-429E-411C-A066-660CE5F57F05 Q35484805-9B424716-680C-41AA-BD00-D0B4F91FD2E4 Q35614156-4ED70305-D7C8-4026-B1E9-26AB444D4DDE Q36089350-972C3CE2-8B28-41BA-8567-BF51517FB4C2 Q36351543-B4267550-81B8-4E4A-9BDB-BAD5190E5C77 Q36425995-4AD0796D-4B8C-4F10-AFCA-E00E4A844367 Q36806669-899AABE8-DB66-44D5-AD30-5482263098B0 Q36808034-7B9291D2-D455-4987-9B14-319A1DD25AC8 Q36847271-94561992-7024-43C5-B78D-CC35F88EFB99 Q37029454-C88BC643-23CF-445B-AFB8-FEF13892DE75 Q37098986-1E43C0CB-5448-47B9-93AF-E841D160BEDF Q37166113-8C0E8EC9-28AB-4053-9719-FFE9E7569F57 Q37552865-0D6AEBEF-2A22-46B5-B25A-009243CB4F26 Q37862378-E72ABF52-AFE0-457D-A3F7-978596D33011 Q37950422-E0217135-8766-4DEF-B474-C7667052C6B5 Q37957772-C783CA08-110A-4E2C-864D-1FB146883189 Q38081485-453F63ED-3FE3-405B-9DE8-337B2098D0CE Q38118061-CDA40DD7-0392-4A07-B37B-07BAC988DEE2 Q38213306-0C6FB052-459E-4A30-B4A2-C395264D4F30 Q38258699-E3592B93-A5CC-4130-9175-58EB57163CD4 Q38260932-124932C2-1110-4BA6-9AD4-2FF6E2C49E90 Q38588201-FE1F1D2C-4698-4D52-A223-547BC9E701C5 Q38593798-B6B4E9D4-36F4-4E34-B2FC-BE0DC0E4F83C Q38768169-D07A907A-324E-4CEC-8BE2-ACF658717971

P2860

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

http://www.wikidata.org/entity/Q35572611

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Clozapine in drug induced psyc ...... lled study with open follow up

@ast

Clozapine in drug induced psyc ...... lled study with open follow up

@en

type

label

Clozapine in drug induced psyc ...... lled study with open follow up

@ast

Clozapine in drug induced psyc ...... lled study with open follow up

@en

prefLabel

Clozapine in drug induced psyc ...... lled study with open follow up

@ast

Clozapine in drug induced psyc ...... lled study with open follow up

@en

P1433

Q35572611-3F37B493-C5F5-4D36-BFA2-185026211940

P1476

Q35572611-4DA91A01-2650-4F3E-823D-7FB8F0016A47

P2093

Q35572611-140C2356-66C6-4047-8A6A-C9202C1311D9

Q35572611-20E25CF4-5F6E-4DC5-AE9D-953CA59446E9

Q35572611-34769BCE-0310-4A1B-8D3D-32401702D303

Q35572611-4579FF35-92F9-415E-A762-D66F2400A619

Q35572611-517E367D-738F-40B4-B5D0-D352682221EE

Q35572611-630C75E4-FFF8-41C0-82A9-CEA016A7635C

Q35572611-B2613D06-686B-4045-BEC3-CF2C6A45D035

Q35572611-C2E3D9D2-8F5A-427D-8F31-84BFE9842E53

P2860

Q35572611-0086055A-7526-47E6-96CD-6B004E2383A4

Q35572611-08A31ECD-2602-451D-ACD9-7E5D1807E079

Q35572611-1E0C669D-5904-4A16-85F0-BE372364CA94

Q35572611-4BB0ACB3-0821-41C9-8B44-278A3C7FB723

Q35572611-5C454893-CE5B-48C8-9E95-E2EF8B226D80

Q35572611-6077F7F3-6B11-4DB9-B463-220DB68387A3

Q35572611-6885D257-B27A-414E-AA8E-D4D5E70F5376

Q35572611-70CD43E6-90BA-409E-A113-36D6C0942152

Q35572611-90C152EE-1B0A-419C-AE63-212FE423BCCC

Q35572611-9E491F07-DFA6-41E5-8D13-403C3DD694A4

P304

Q35572611-A5065551-27C7-4400-816A-9C3DF9B1CFC5

P31

Q35572611-0450EEEB-81C6-4E45-8834-2F8F6FBC6BF8

P356

Q35572611-5FAD9E7E-488F-43F2-B60C-FBD5080B1BAD

P407

Q35572611-EC56A0CF-6735-4FFE-97DC-96F697A05F50

P433

Q35572611-D5A0255B-1092-49EA-AF42-E73D181B5BE0

P478

Q35572611-7250C51F-BF8B-4E5D-9272-FA2AFE6F2257

P577

Q35572611-634FD9D9-49BE-4D4C-9CDC-59700E5DBC0D

P5875

Q35572611-45041F50-F638-4529-A627-A1EDC2ECFF70

P698

Q35572611-7F2ACC66-009A-463B-AB89-B4D7743F7F11

P921

Q35572611-6113F7D6-C98B-4778-BDCE-57FDB25F398A

Q35572611-7C971E6F-0283-4890-9F05-9A5DB1678FAC

Q35572611-D62630ED-BC7F-4291-8750-4F7A3B91E8FF

P932

Q35572611-5EADD293-C619-417D-A2F0-C71EEB705BC8

P356

JNNP.2003.029868

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Clozapine in drug induced psyc ...... lled study with open follow up

@en

P2093

Bourdeix I

http://www.w3.org/2001/XMLSchema#string

Destée A

http://www.w3.org/2001/XMLSchema#string

Durif F

http://www.w3.org/2001/XMLSchema#string

Pollak P

http://www.w3.org/2001/XMLSchema#string

Péré JJ

http://www.w3.org/2001/XMLSchema#string

Rascol O

http://www.w3.org/2001/XMLSchema#string

Senard JM

http://www.w3.org/2001/XMLSchema#string

Tison F

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.

Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.

Psychosis: impact on the patient and family.

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

The management of the levodopa psychoses.

Parkinson's disease: drug-induced psychiatric states.

Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients.

P304

689-695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP.2003.029868

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2004-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8612240

http://www.w3.org/2001/XMLSchema#string

P698

15090561

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

1763590

http://www.w3.org/2001/XMLSchema#string